Drugs / M2-BFs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04689282 | Feb 2020 → Sep 2021 | attention deficit-hyperactivity disorder, autism spectrum disorder, expressive language disorder, speech disorder | Russian Academy of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M2-BFs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04689282 ↗ |
| Known as | Bioactive Factors, Produced by M2 Type Macrophages | “Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs).” NCT04689282 ↗ |
| Route | Intranasal | “Intranasal delivery of M2-BFs is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.” NCT04689282 ↗ |